4 ms·
It wouldn't have mattered much in practice. Astrazeneca has also produced a vaccine and it's not an mRNA vaccine. Not trying to downplay the research here, I'm
by cinntaile 6y ago
It wouldn't have mattered much in practice.
Astrazeneca has also produced a vaccine and it's not an mRNA vaccine.
Not trying to downplay the research here, I'm just talking timing.
- maxerickson 6y agoAt about the same time, Pfizer and BioNTech spoke with Graham about using the 2P mutation in their vaccine. Because their work was patented and widely published, other drugmakers—including Novavax and Johnson & Johnson—also based their candidates on the design. Pfizer-BioNTech’s vaccine would become the first authorized in the U.S. after it showed an impressive 95-percent efficacy rate. Moderna’s vaccine was 94-percent effective. (at least) 4 of the vaccine candidates utilize the research from the article.
- glandium 6y agoThe technology used for the Oxford/Astrazeneca vaccine, AIUI, was years in the making, and wasn't ready either a few years ago. Again, good timing.